Document:

Exhibit 10.13

 

CHECKPOINT
THERAPEUTICS, INC.

NON-EMPLOYEE
DIRECTORS COMPENSATION PLAN

 

     

     

    

 

CHECKPOINT
THERAPEUTICS, INC.

NON-EMPLOYEE
DIRECTORS COMPENSATION PLAN

 

ARTICLE 1

PURPOSE

 

1.1.          Purpose.
The purpose of the Checkpoint Therapeutics, Inc. Non-Employee Directors Compensation Plan is to attract, retain and compensate
highly-qualified individuals who are not employees of Checkpoint Therapeutics, Inc. or any of its Subsidiaries or Affiliates for
service as members of the Board by providing them with competitive compensation and an opportunity to participate in the Company’s
future growth through the granting of stock-based incentive awards. The Company intends that the Plan will benefit the Company
and its stockholders by allowing Non-Employee Directors to have a personal financial stake in the Company through an ownership
interest in the Stock and will closely associate the interests of Non-Employee Directors with that of the Company’s stockholders.

 

1.2.          ELIGIBILITY.
All Non-Employee Directors shall automatically be participants in the Plan.

 

ARTICLE 2

DEFINITIONS

 

2.1.          DEFINITIONS.
Capitalized terms used herein and not otherwise defined shall have the meanings given such terms in the LTIP.  Unless
the context clearly indicates otherwise, the following terms shall have the following meanings:

 

		(a)	“Annual Equity Award” means stock options, stock awards, restricted stock, restricted
stock units, stock appreciation rights, or other awards based on or derived from the Stock which are authorized under this Plan
for award to Non-Employee Directors under Section 6.2 of the Plan.

 

		(b)	“Award” means any Initial Equity Award or Annual Equity Award granted to a Non-Employee
Director under Article 6 of the Plan.

 

		(c)	“Basic Cash Retainer” means the annual cash retainer (excluding any Supplemental Cash
Retainer, Meeting Fees and expenses) payable by the Company to a Non-Employee Director pursuant to Section 5.1 hereof for service
as a director of the Company, as established from time to time by the Board and set forth in Schedule I hereto.

 

		(d)	“Company” means Checkpoint Therapeutics, Inc., a Delaware corporation.

 

		(e)	“Initial Equity Award” means stock options, stock awards, restricted stock, restricted
stock units, stock appreciation rights, or other awards based on or derived from the Stock which are authorized under this Plan
for award to Non-Employee Directors under Section 6.1 of the Plan.

 

		(f)	“LTIP” means the Checkpoint Therapeutics, Inc.
Amended and Restated 2015 Incentive Plan, or any subsequent equity compensation plan approved by the Board and designated as the
LTIP for purposes of this Plan.

 

     

     

    

  

		(g)	“Meeting Fees” means fees for attending a meeting of the Board or one of its Committees
as set forth in Section 5.3 hereof.

 

		(h)	“Non-Employee Director” means a director of the Company who is not an employee of the
Company or any of its Subsidiaries or Affiliates.

 

		(i)	“Plan” means the Checkpoint Therapeutics, Inc. Non-Employee Directors Compensation
Plan, as amended from time to time.

 

		(j)	“Plan Year(s)” means the approximate twelve-month periods between annual meetings of
the stockholders of the Company.

 

		(k)	“Supplemental Cash Retainer” means the supplemental annual cash retainer (excluding
Basic Cash Retainer, Meeting Fees and expenses) payable by the Company to a Non-Employee Director pursuant to Section 5.2 hereof
for service as Chairman of the Board, Lead Director, or chair of a committee of the Board, as established from time to time by
the Board and set forth in Schedule I hereto.

 

ARTICLE 3

ADMINISTRATION

 

3.1.          ADMINISTRATION.
The Plan shall be administered by the Board, or, at the discretion of the Board from time to time, the Plan may be administered
by a committee of the Board. Subject to the provisions of the Plan, the Board shall be authorized to interpret the Plan, to establish,
amend and rescind any rules and regulations relating to the Plan, and to make all other determinations necessary or advisable for
the administration of the Plan. The Board’s interpretation of the Plan, and all actions taken and determinations made by
the Board pursuant to the powers vested in it hereunder, shall be conclusive and binding upon all parties concerned including the
Company, its stockholders and persons granted awards under the Plan. The Board may appoint a plan administrator to carry out the
ministerial functions of the Plan, but the administrator shall have no other authority or powers of the Board. To the extent the
Board has delegated any authority and responsibility under this Plan to a committee of the Board, such committee shall have the
powers and protections of the Board hereunder, and any reference herein to the Board (other than in this Section 4.1) shall include
such committee. To the extent any action of the Board under the Plan conflicts with actions taken by such committee, the actions
of the Board shall control.

 

3.2.          RELIANCE.
In administering the Plan, the Board may rely upon any information furnished by the Company, its public accountants and other experts.
No individual will have personal liability by reason of anything done or omitted to be done by the Company or the Board in connection
with the Plan.

 

3.3.          INDEMNIFICATION.
Each person who is or has been a member of the Board or who otherwise participates in the administration or operation of the Plan
shall be indemnified by the Company against, and held harmless from, any loss, cost, liability or expense that may be imposed upon
or incurred by him or her in connection with or resulting from any claim, action, suit or proceeding in which such person may be
involved by reason of any action taken or failure to act under the Plan and shall be fully reimbursed by the Company for any and
all amounts paid by such person in satisfaction of judgment against him or her in any such action, suit or proceeding, provided
he or she will give the Company an opportunity, by written notice to the Board, to defend the same at the Company’s own expense
before he or she undertakes to defend it on his or her own behalf. This right of indemnification shall not be exclusive of any
other rights of indemnification.

 

    	 	– 2 –	 

     

    

  

ARTICLE 4

SHARES

 

4.1.          SOURCE
OF SHARES FOR THE PLAN. The Awards and shares of Stock that may be issued pursuant to the Plan shall be issued under
the LTIP, subject to all of the terms and conditions of the LTIP, including but not limited to Section 5.1 of the LTIP, which provides
that the maximum aggregate number of Shares associated with any Award granted under this Plan in any calendar year to any one Non-Employee
Director shall be 100,000 Shares. The terms contained in the LTIP are incorporated into and made a part of this Plan with respect
to Awards granted pursuant hereto, and any such Awards shall be governed by and construed in accordance with the LTIP. In the event
of any actual or alleged conflict between the provisions of the LTIP and the provisions of this Plan, the provisions of the LTIP
shall be controlling and determinative. The Plan is considered to be and shall be operated as a subplan of the LTIP, and does not
constitute a separate source of shares for the grant of the Awards provided herein.

 

ARTICLE 5

CASH COMPENSATION

 

5.1.          BASIC
CASH RETAINER.  Each Non-Employee Director shall be paid a Basic Cash Retainer for service as a director during each
Plan Year, payable in advance, on the first business day following each annual meeting of stockholders. The amount of the Basic
Cash Retainer shall be established from time to time by the Board. The amount of the Basic Cash Retainer is set forth in Schedule
I, as amended from time to time by the Board. Each person who first becomes an Non-Employee Director on a date other than an
annual meeting date shall be paid a pro rata amount of the Basic Cash Retainer for that Plan Year to reflect the actual number
of days served in the Plan Year.

 

5.2.          SUPPLEMENTAL
CASH RETAINER.  The Chairman of the Board, Lead Director, and chairs of each committee of the Board may be paid a Supplemental
Cash Retainer during a Plan Year, payable at the same times as installments of the Basic Cash Retainer are paid. The amount of
the Supplemental Cash Retainers shall be established from time to time by the Board, and shall be set forth in Schedule I,
as amended from time to time by the Board. A pro rata Supplemental Cash Retainer will be paid to any Non-Employee Director who
is elected by the Board to a position eligible for a Supplemental Cash Retainer on a date other than the beginning of a Plan Year,
to reflect the actual number of days served in such eligible capacity during the Plan Year.

 

5.3.          MEETING
FEES.  Each Non-Employee Director may be paid a fee for each meeting of the Board or committee thereof in which
he or she participates. The amount of the fees, if any, shall be established from time to time by the Board and shall be set forth
in Schedule I, as amended from time to time by the Board. For purposes of this provision, casual or unscheduled conferences
among directors shall not constitute an official meeting.

 

5.4.          EXPENSE
REIMBURSEMENT. All Non-Employee Directors shall be reimbursed for reasonable travel and out-of-pocket expenses in connection
with attendance at meetings of the Board and its committees, or other Company functions at which the Chief Executive Officer, Chairman
of the Board, or Lead Director requests the director to participate.

 

    	 	– 3 –	 

     

    

  

ARTICLE 6

EQUITY AWARDS

 

6.1           INITIAL
EQUITY AWARD. Subject to share availability under the LTIP, on the first date a Non-Employee Director is initially elected
or appointed to the Board, he or she shall be granted an Initial Equity Award. The Initial Equity Award is set forth in Schedule
I, as amended from time to time by the Board. Such Initial Equity Award shall be subject to the terms and restrictions described
in Schedule I and below in this Article 6.

 

6.2           ANNUAL
EQUITY AWARD. Subject to share availability under the LTIP, on the day following each annual meeting of the Company’s
stockholders, each Non-Employee Director serving as such on that date (other than a director who first became a Non-Employee Director
at the stockholders meeting held on the previous day) shall be granted an Annual Equity Award. The Annual Equity Award is set forth
in Schedule I, as amended from time to time by the Board. Such Annual Equity Award shall be subject to the terms and restrictions
described in Schedule I and below in this Article 6.

 

6.3           TERMS
AND CONDITIONS OF AWARDS. Awards granted under this Article 6 shall be subject to the terms and conditions described below
and in the LTIP.

 

		(a)	Vesting. Each Award granted under this Plan shall vest as provided in Schedule I,
as amended from time to time by the Board; provided, however, that each Award shall become fully vested upon the occurrence of
a Change of Control.

 

		(b)	Effect of Termination of Directorship. Upon termination of a Non-Employee Director’s
membership on the Board for any reason (including without limitation, by reason of death, Disability, retirement or failure to
be re-nominated or re-elected as a director), the Non-Employee Director shall forfeit all of his or her right, title and interest
in and to any unvested portion of the Initial Equity Award or Annual Equity Award, as the case may be.

 

		(c)	Award Certificates. All Awards shall be evidenced by a written Award Certificate between
the Company and the Non-Employee Director, which shall include such provisions, not inconsistent with the Plan or the LTIP, as
may be specified by the Board.

 

6.4           ADJUSTMENTS.
The adjustment provisions of the LTIP shall apply with respect to Awards granted pursuant to this Plan. Without limiting the foregoing,
in the event of a subdivision of the outstanding Stock (stock-split), a declaration of a dividend payable in shares of Stock, or
a combination or consolidation of the outstanding Stock into a lesser number of shares of Stock, the number of Awards to be granted
to Non-Employee Directors in accordance with Article 6 hereof shall be adjusted proportionately and the shares of Stock then subject
to each Award shall automatically be adjusted proportionately without any change in the aggregate purchase price therefore.

 

ARTICLE 7

Amendment,
Modification and Termination

 

7.1.          AMENDMENT,
MODIFICATION AND TERMINATION. The Board may, at any time and from time to time, amend, modify or terminate the Plan without
stockholder approval; provided, however, that if an amendment to the Plan would, in the reasonable opinion of the Board, require
stockholder approval under applicable laws, policies or regulations or the applicable listing or other requirements of a securities
exchange on which the Stock is listed or traded, then such amendment shall be subject to stockholder approval; and provided further,
that the Board may condition any other amendment or modification on the approval of stockholders of the Company for any reason.

 

    	 	– 4 –	 

     

    

  

ARTICLE 8

General
Provisions

 

8.1.          EXPENSES
OF THE PLAN. The expenses of administering the Plan shall be borne by the Company.

 

8.2.          EFFECTIVE
DATE AND DURATION OF THE PLAN. The Plan shall be effective as of the date it is approved by the Board. The Plan shall remain
in effect until terminated by the Board.

 

	 	CHECKPOINT THERAPEUTICS, Inc.
	 	 
	 	By:	/s/ James F. Oliviero, President & CEO

 

    	 	– 5 –	 

     

    

  

SCHEDULE I

 

Effective as of January 8, 2016

 

The following shall remain in effect until
changed by the Board:

 

	Basic Cash Retainer:	
        $50,000, paid quarterly in advance ($12,500
        per quarter).

         

	
        Supplemental Cash 

        Retainer for Audit Chair:
	
         

        $10,000, paid quarterly in advance ($2,500
        per quarter).

         

	Initial Equity Award:	
        50,000 shares of Restricted Stock, which
        shares shall vest and become non-forfeitable in equal annual installments over three years, beginning on the third (3rd)
        anniversary of the Grant Date, subject to the Non-Employee Director’s continued service on the Board on such date.

         

	Annual Equity Award:	
        The greater of (i) a number of shares of
        Restricted Stock having a fair market value on the Grant Date of $50,000, or (ii) 10,000 shares of Restricted Stock, which shares
        shall vest and become non-forfeitable on the third (3rd) anniversary of the Grant Date, subject to the Non-Employee
        Director’s continued service on the Board on such date.

         

 

    	 	– 6 –Exhibit 10.14

 

CONFIDENTIAL TREATMENT REQUESTED. Confidential portions of
this document have been redacted and have been separately filed with the Commission.

 

OPTION AGREEMENT

 

This Option Agreement (the “Agreement”) dated as
of March 17, 2015 (the “Effective Date”), is entered into by and between Fortress Biotech, Inc. (“Fortress”),
a Delaware Corporation having a place of business at 3 Columbus Circle, 15th Floor, New York, NY 10019, and TG Therapeutics,
Inc. (“TG”), a Delaware Corporation having a place of business at 3 Columbus Circle, 15th Floor, New York,
NY 10019, with respect to the following:

 

WHEREAS, Fortress entered into a
license agreement (the “License Agreement”) with NeuPharma, Inc. (“NeuPharma”) dated as of March 17, 2015,
pursuant to which Fortress licensed certain intellectual property rights with respect to Compounds and owns or controls certain
know-how, technology, documentation, data, and other materials relating thereto; Capitalized terms used herein but not otherwise
defined herein shall have the meanings ascribed to such terms in the License Agreement;

 

WHEREAS, Fortress wishes to grant,
and TG wishes to receive, an option to enter into a global collaboration in the Territory for such intellectual property rights
with respect to the Compounds and the know-how, technology, documentation, data, and other materials relating thereto, all on the
terms and subject to the conditions set forth in this Agreement;

 

NOW, THEREFORE, in consideration
of the foregoing premises and the mutual covenants herein contained, and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

 

		1.	Definitions.

 

For purposes of this Agreement, the following terms
shall have the following meanings:

 

		1.1.	“Confidential Information” shall mean, with respect to a party, all information (and all tangible and intangible
embodiments thereof), which is owned or controlled by such party, and is disclosed by such party to the other party in connection
with this Agreement (whether prior to or following the Effective Date). Nothwithstanding the foregoing, Confidential Information
of a party shall not include information which, and only to the extent that, the receiving party (the “Recipient”)
can demonstrate that (a) the disclosed information was public knowledge at the time of such disclosure to the Recipient, or thereafter
became public knowledge, other than as a result of actions of the Recipient in violation hereof; (b) the disclosed information
was rightfully known by the Recipient (as shown by its written records) prior to the date of disclosure to the Recipient by the
other party without a duty of confidentiality to any party; (c) the disclosed information was disclosed to the Recipient on an
unrestricted basis from a source unrelated to any party to this Agreement and not under a duty of confidentiality to the other
party; or (d) the disclosed information was independently developed by the Recipient without use of the Confidential Information
disclosed by the other party.

 

     

     

    

 

		1.2.	“Collaboration Agreement” shall mean a definitive global collaboration agreement between the parties, in
a form mutually acceptable to the parties and incorporating the terms and conditions set forth in Exhibit A.

 

		1.3.	“Field” all prophylactic, palliative, therapeutic or diagnostic uses in humans or animals for the prevention,
diagnosis and treatment of hematological malignancies, including, without limitation, all Leukemia’s, Lymphoma’s, Multiple
Myeloma and Waldentroms Macroglobulemia. Additionally, the Field shall include the prevention, diagnosis and treatment of Autoimmune
Diseases, which shall mean any disease which results from a loss of immune tolerance to self-antigens, including without limitation
multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, sjogren syndrome, celiac disease, Graves’ disease,
myasthenia gravis, Type I diabetes, idiopathic thrombocytopenic purpura, pemphigus vulgaris, among others, including any presentation
or manifestation thereof.

 

		1.4.	“Option” shall mean the exclusive option set forth in Section 3.2.

 

		1.5.	“Option Period” shall mean the period ending on the date that is 180 days following the Effective Date;
subject to a 3-month extension upon prior written consent of Fortress, not to be unreasonably withheld.

 

		2.	Representations and Warranties.

 

		2.1.	Mutual Representations and Warranties. Each party hereby represents and warrants to the other party as follows:

 

		2.1.1.	Existence. Such party is duly organized, validly existing and in good standing under the laws of the jurisdiction in
which it is organized.

 

		2.1.2.	Authorization and Enforcement of Obligations. Such party (a) has the requisite power and authority and the legal right
to enter into this Agreement and to perform its obligations hereunder, and (b) has taken all necessary actions on its part to authorize
the execution and delivery of this Agreement and the performance of its obligations hereunder. This Agreement has been duly executed
and delivered on behalf of such party, and constitutes a legal, valid, binding obligation enforceable against such party in accordance
with its terms.

 

		2.1.3.	No Conflict. The execution and delivery of this Agreement and the performance of such party’s obligations hereunder
(a) do not conflict or violate any requirements of applicable laws or regulations, and (b) do not conflict with, or constitute
default under, any contractual obligations of such party.

 

    	 	2	 

     

    

 

		2.2.	Products. Fortress represents and warrants to TG that, as of the Effective Date, Fortress owns or has rights to the
Compounds.

 

		3.	Option.

 

		3.1.	Option Consideration. Upon the execution of this Agreement, TG shall pay to Fortress $25,000 as consideration for granting
the Option (the “Option Fee”).

 

		3.2.	Grant of Option. In consideration of the Option Fee, Fortress hereby grants to TG an exclusive (as defined below in
this Section 3.2) option to enter into a collaboration for the Compounds in the Field and Territory (the “Collaboration Option”)
on the terms described in Exhibit A. For purposes of this Section 3.2, “exclusive” means that during the Option Period,
Fortress will not grant a third party a license or enter into a collaboration to make, use or sell Compounds in the Territory and
Field.

 

		3.3.	Exercise of Option. During the Option Period, TG shall have the right, but not the obligation, within its sole discretion,
to exercise the Option by delivering written notice of such exercise (the “Exercise Notice”) to Fortress. Upon
exercise of the Option, Fortress and TG shall negotiate the Collaboration Agreement in good faith and upon agreement to the terms
therefore, will execute the Collaboration Agreement.

 

		3.4.	TG agrees that it shall not, except as set forth in the Option Agreement, exercise any rights to the Compounds. In the event
the parties do not execute the Collaboration Agreement prior to the expiration of the Option Period, the Option shall expire and
(i) Fortress shall be free to grant a third party a license to make, use or sell Compounds in the Territory and Field and (ii)
TG shall not exercise any rights under to the Compounds. This Section 3.4 shall survive the expiration or termination of this Agreement.

 

		4.	Confidentiality.

 

		4.1.	Confidential Information. During the term of this Agreement, and for a period of five (5) years following the termination
hereof, each party shall maintain in confidence the Confidential Information of the other party, and shall not use, disclose or
grant the use of the Confidential Information except on a need-to-know basis to those directors, officers, affiliates employees,
permitted licensees, permitted assignees and agents, consultants, clinical investigators or contractors, to the extent such disclosure
is reasonably necessary in connection with performing its obligations or exercising its rights under this Agreement. To the extent
that disclosure is authorized by this Agreement, prior to such disclosure, each party hereto shall obtain agreement of any such
person to hold in confidence and not make sure of the Confidential information for any purpose other than those permitted by this
Agreement. Each party shall notify the other promptly upon discovery of any unauthorized use or disclosure of the other party’s
Confidential information.

 

    	 	3	 

     

    

 

		4.2.	Permitted Disclosures. The confidentiality obligations contained in this Section 4 shall not apply to the extent that
Recipient is required (a) to disclose information by law, regulation, or order of a governmental agency or a court of competent
jurisdiction, or (b) to disclose information to any governmental agency for purposes of obtaining approval to test or market a
product, provided in either case that the Recipient shall provide written notice hereof to the other party and sufficient opportunity
to object to any such disclosure or to request confidential treatment hereof.

 

		5.	Limitation of Liability. NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY OR ANY THIRD PARTY IN ANY MANNER, UNDER ANY
THEORY OF LIABILITY, WHETHER IN CONTRACT, TORT (INCLUDING WITHOUT LIMITATION NEGLIGENCE), INDEMNITY, BREACH OF WARRANTY, OR OTHER
THEORY, FOR ANY INDIRECT, CONSEQUENTIAL, INCIDENTAL, EXEMPLARY, PUNITIVE, STATUTORY OR SPECIAL DAMAGES, INCLUDING LOST PROFITS
AND LOSS OF DATA, REGARDLESS OF WHETHER SUCH PARTY WAS ADVISED OF OR WAS AWARE OF THE POSSIBILITY OF SUCH DAMAGES.

 

		6.	Term: Termination.

 

		6.1.	Term. This Agreement shall commence on the Effective Date and, unless earlier terminated pursuant to Section 6.2, shall
terminate upon expiration of the Option Period.

 

		6.2.	Termination.

 

		6.2.1.	If a party has materially breached any of its obligations hereunder, and such material breach shall continue for thirty (30)
days after written notice of such breach was provided to the breaching party, the nonbreaching party shall have the right, at its
option, to terminate this Agreement effective at the end of such thirty (30) day period.

 

		6.2.2.	TG may terminate this Agreement for its convenience by providing thirty (30) days advanced written notice to Fortress.

 

		6.3.	Effect of Expiration or Termination. Expiration or termination of this Agreement shall not relieve the parties of any
obligation accruing prior to such expiration or termination and the provisions of Sections 4, 5, 6.3, and 7 shall survive the expiration
or termination of this Agreement.

 

		7.	Miscellaneous.

 

		7.1.	Entire Agreement. This Agreement and all exhibits and schedules hereto embody the entire agreement between the parties
and supersedes any prior representations, understandings, and agreements between the parties regarding the subject matter hereof.
There are no representations, understandings, or agreements, oral or written, between the parties regarding the subject matter
hereof that are not fully expressed herein.

 

    	 	4	 

     

    

 

		7.2.	Severability. Any of the provisions of this Agreement which are determined to be invalid or unenforceable in any jurisdiction
shall be ineffective to the extent such invalidity or unenforceability in such jurisdiction, without rendering invalid or unenforceable
the remaining provisions hereof, and without affecting the validity or enforceability of any of the terms of this Agreement in
any other jurisdiction.

 

		7.3.	Notices. Any consent, notice, or report required or permitted to be given or made under this Agreement by one of the
parties hereto to the other party shall be in writing, delivered by any lawful means to such other party at its address indicated
below, or to such other address as the addressee shall have last furnished in writing to the addressor and (except as otherwise
provided in this Agreement) shall be effective upon receipt by the addressee. Notice shall be addressed as followed:

 

	To TG:	TG Therapeutics, Inc.

3 Columbus Circle, 15th Floor

New York, NY 10019 USA 

Attn.  Michael S. Weiss
	 	 
	To Fortress:	Fortress Biotech, Inc.

3 Columbus Circle, 15th Floor 

New York, NY 10019

Attn.  Lindsay Rosenwald

 

		7.4.	Assignment. Neither party shall assign its rights or obligations under this Agreement without the prior written consent
of the other party, provided however, that each party may, without such consent, assign this Agreement and its rights and obligations
hereunder (a) to any Affiliate, or (b) in connection with the transfer or sale of all or substantially all of its business to which
this Agreement relates, or in the event of its merger, consolidation, change in control or similar transaction. Any permitted assignee
shall assume all obligations of its assignor under this Agreement.

 

		7.5.	Headings. The section headings are for convenience only and are not a part of this Agreement.

 

		7.6.	Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original,
but all of which together shall constitute one and the same instrument.

 

		7.7.	Waiver. The waiver by either party hereto of any right hereunder or the failure to perform or of a breach by the other
party shall not be deemed a waiver of any other right hereunder or of any other breach or failure by said other party whether of
a similar nature or otherwise.

 

    	 	5	 

     

    

 

		7.8.	Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York,
without regard to the conflicts of law principles thereof.

 

In Witness Whereof, the parties have executed this Agreement
effective as of the Effective Date.

 

	TG Therapeutics, Inc.	 
	 	 
	/s/ Michael S. Weiss	 
	By: Michael S. Weiss 	 
	Title: Chief Executive Officer   	 
	 	 
	Fortress Biotech, Inc.	 
	 	 
	/s/ Michael S. Weiss	 
	By: Michael S. Weiss	 
	Title: Executive Vice Chairman	 

 

    	 	6	 

     

    

 

CONFIDENTIAL TREATMENT REQUESTED. Confidential portions of
this document have been redacted and have been separately filed with the Commission.

  

EXHIBIT A - TERM
SHEET

 

	COMPOUNDS	As defined in the License Agreement
	 	 
	FORTRESS KNOW-HOW	As defined as “Know-How” in the License Agreement
	 	 
	FORTRESS Patents	As defined as “Licensor Patents” in the License Agreement
	 	 
	TERRITORY	As defined in the License Agreement.
	 	 
	FIELD OF USE	As defined in the Option Agreement; provided that any BTK inhibitors discovered under the Sponsored Research Agreement with NeuPharma funded by TGTX, the Field of Use shall not be restricted and shall include all uses under the License Agreement.
	 	 
	DIRECT SALES ROYALTIES	*% royalties on Net sales > $*

  

*% royalties on Net sales >$* but <$*

  

*% royalties on Net Sales >$*

 

 

* Confidential
material redacted and filed separately with the Commission.

 

    	 	Exhibit A-1	 

     

    

 

	
        MILESTONE PAYMENTS

         

        TO FORTRESS
	
        The following amounts within 20 days of the following milestones:

         

        Upon Exercise of Option: $*

         

        1: $* – *

         

        2: $* – *

         

        3: $* – *

         

        4: $* on *

         

        5: $* on *

         

        6: $* on *

         

        7: $* on *

         

        8: $* on *

         

        9: $* on *

         

        Milestones 2-7 above shall be payable one time for any Product
        (including RX518) primarily targeting EGFR. For any Product primarily targeting BTK, Milestones 2-7 shall be payable for each of
        the first three Indications for which Product achieves the respective Product Milestone Event.

 

 

* Confidential
material redacted and filed separately with the Commission.

 

    	 	Exhibit A-2	 

     

    

 

	RESPONSIBILITIES OF THE PARTIES	
        The parties shall share the costs of all IND-Enabling work 50/50.
        IND-Enabling costs shall include, without limitation, all pre-clinical toxicology, pharmacology, CMC, and other work required for
        the filing of an IND. These costs shall include only external costs incurred and each party shall be responsible for internal costs
        (personnel, overhead, etc.) incurred in connection with the IND filing. Each party shall pay the costs of filing their own IND
        and thereafter, TG shall be responsible for 100% of the clinical development, drug supply, and commercialization costs and expenses
        of developing the Compounds in the Field. Parties shall share CMC and formulation development costs.

         

        TG shall pay individually for any specific experiments that
        relate solely to the BTK properties of the Compounds. Any Compounds that target BTK and are derived from the sponsored research
        by TG, TG shall be responsible for the full costs of development and commercialization and will have full worldwide rights to these
        Compounds under the License Agreement.

	 	 
	GOVERNING LAW	The Collaboration Agreement shall be governed by the laws of the State of New York without regard to principals of conflicts of law thereof.
	 	 
	Other Provisions	The Agreement would also contain additional customary terms and conditions agreed by the Parties.
	 	 
	EFFECT OF TERM SHEET	The terms and conditions set forth in this Exhibit A shall not be binding on either party until such time as the parties enter into the Collaboration Agreement.

 

    	 	Exhibit A-3	 

     

    

 

 

September 11, 2015

 

Dr. Lindsay Rosenwald

Fortress Biotech, Inc.

3 Columbus Circle, 15th
Floor

New York, NY 10019

 

Mr. Michael Weiss

Checkpoint Therapeutics,
Inc.

3 Columbus Circle, 15th
Floor

New York, NY 10019

 

EXTENSION
OF OPTION AGREEMENT

 

Gentlemen:

 

As
discussed, we would like to extend the Option Period in the Option Agreement dated March 17, 2015 (the “Option Agreement”)
between TG Therapeutics, Inc. and Fortress Biotech, Inc.

 

1.          Parties.
Effective March 17, 2015, Fortress and the Checkpoint Therapeutics, Inc. (“Checkpoint”) entered into an agreement pursuant
to which Fortress assigned to Checkpoint all of its right and interests under the License Agreement.

 

2.          Option
Period. Pursuant to Section 1.5 of the Option Agreement, the Option Period shall mean the date that is 180 days following
the Effective Date; subject to a 3-month extension upon prior written request, not to be unreasonably withheld. As such, the Parties
agree to extend the Option Period for 3 months, with an expiration date of December 17, 2015.

 

3.          Terms.
The Amendment shall be governed under all of the same terms as the Option Agreement.

 

4.          Defined
Terms. Any capitalized term not defined in this Amendment shall be defined as defined in the Option Agreement.

 

5.          Counterparts.
This Amendment may be executed by any party by PDF file signature, and on one or more counterparts, and by different parties on
separate counterparts, each of which shall be deemed to be an original as against any party whose signature appears thereon, all
of which together shall constitute but one and the same instrument.

 

 

TG Therapeutics,
Inc.

3 Columbus
Circle, 15th Floor

New York,
NY 10019

 

     

     

    

 

	 	Sincerely,
	 	TG Therapeutics, Inc.
	 	 
	 	/s/  Michael S. Weiss
	 	By: Michael S. Weiss
	 	Title: Executive Chairman, Interim CEO
	
        Agreed and Accepted
by:
	 
	Fortress Biotech, Inc.	 

 

	/s/ Lindsay Rosenwald	 
	By: Dr. Lindsay Rosenwald 	 
	Title: Chief Executive Officer	 
	 	 
	Agreed and Accepted by:	 
	Checkpoint Therapeutics, Inc.	 
	 	 
	/s/ Michael S. Weiss	 
	By: Mr. Michael S. Weiss	 
	Title: Executive Chairman, Interim CEO and President	 

 

     

     

    

 

 

December 15, 2015

 

Mr. James Oliviero

Checkpoint Therapeutics, Inc.

3 Columbus Circle, 15th
Floor

New York, NY 10019

 

EXTENSION
OF OPTION AGREEMENT

 

Dear James:

 

As
discussed, we would like to extend the Option Period in the Option Agreement dated March 17, 2015 (the “Option Agreement”)
between TG Therapeutics, Inc. and Fortress Biotech, Inc. (“Fortress”), as previously extended on September 11, 2015.

 

1.          Parties.
Effective March 17, 2015, Fortress and Checkpoint Therapeutics, Inc. (“Checkpoint") entered into an agreement pursuant
to which Fortress assigned to Checkpoint all of its right and interests under the License Agreement.

 

2.          Option
Period. Pursuant to Section 1.5 of the Option Agreement, the Option Period shall mean the date that is 180 days following
the Effective Date; subject to a 3-month extension upon prior written request, not to be unreasonably withheld. The parties agree
to further extend the Option Period for an additional 30 days, with an expiration date of January 17, 2016.

 

3.          Terms.
This Extension of Option Agreement shall be governed under all of the same terms as the Option Agreement.

 

4.          Defined
Terms. Any capitalized term not defined in this Amendment shall be defined as defined in the Option Agreement.

 

5.          Counterparts.
This Amendment may be executed by any party by PDF file signature, and on one or more counterparts, and by different parties on
separate counterparts, each of which shall be deemed to be an original as against any party whose signature appears thereon, all
of which together shall constitute but one and the same instrument.

 

 

TG Therapeutics,
Inc.

3 Columbus
Circle, 15th Floor

New York,
NY 10019

 

     

     

    

  

	 	Sincerely,
	 	TG Therapeutics, Inc.
	 	 
	 	/s/  Michael S. Weiss
	 	By: Michael S. Weiss
	 	Title: Executive Chairman, Interim CEO
	
         Agreed and Accepted by:
	 
	Checkpoint Therapeutics, Inc.	 

  

	/s/ James Oliviero	 
	By: Mr. James Oliviero	 
	Title: CEO and President	 

 

     

     

    

 

 

 

January 11, 2016

 

Mr. James Oliviero

Checkpoint Therapeutics, Inc.

3 Columbus Circle, 15th
Floor

New York, NY 10019

 

EXTENSION
OF OPTION AGREEMENT

 

Dear James:

 

As
discussed, we would like to extend the Option Period in the Option Agreement dated March 17, 2015 (the “Option Agreement”)
between TG Therapeutics, Inc. and Fortress Biotech, Inc. (“Fortress”), as previously extended on September 11, 2015
and December 15, 2015.

 

1.          Parties.
Effective March 17, 2015, Fortress and Checkpoint Therapeutics, Inc. (“Checkpoint”) entered into an agreement pursuant
to which Fortress assigned to Checkpoint all of its right and interests under the License Agreement.

 

2.          Option
Period. Pursuant to Section 1.5 of the Option Agreement, the Option Period shall mean the date that is 180 days following
the Effective Date; subject to a 3-month extension upon prior written request, not to be unreasonably withheld. The parties agree
to further extend the Option Period for an additional 180 days, with an expiration date of July 17, 2016.

 

3.          Terms.
This Extension of Option Agreement shall be governed under all of the same terms as the Option Agreement. The parties hereby acknowledge
and agree that, under the Option Agreement, TG shall pay individually for any specific experiments that relate solely to the BTK
properties of the Compounds. Accordingly, all costs associated with the Research Agreement dated September 15, 2015 between Checkpoint
and NeuPharma shall be borne by TG Therapeutics, with such obligation for this Research Agreement surviving the expiration or earlier
termination of the Option Agreement.

 

4.          Defined
Terms. Any capitalized term not defined in this Amendment shall be defined as defined in the Option Agreement.

 

5.          Counterparts.
This Amendment may be executed by any party by PDF file signature, and on one or more counterparts, and by different parties on
separate counterparts, each of which shall be deemed to be an original as against any party whose signature appears thereon, all
of which together shall constitute but one and the same instrument.

 

 

TG Therapeutics,
Inc.

3 Columbus
Circle, 15th Floor

New York,
NY 10019

 

     

     

    

  

	 	Sincerely,
	 	TG Therapeutics, Inc.
	 	 
	 	/s/ Michael S. Weiss
	 	By: Michael S. Weiss
	 	Title: Executive Chairman, Interim CEO
	 	 
	Agreed and Accepted by: 	 
	Checkpoint Therapeutics, Inc.	 
	 	 
	/s/ James Oliviero	 
	By: Mr. James Oliviero 	 
	Title:
    CEO and President	 

 

     

     

    

 

 

 

July 8, 2016

 

Mr. James Oliviero

Checkpoint Therapeutics, Inc.

2 Gansevoort Street, 9th Floor

New York, NY 10014

 

EXTENSION OF OPTION AGREEMENT

 

Dear James:

 

As discussed, we would
like to extend the Option Period in the Option Agreement dated March 17, 2015 (the “Option Agreement”) between TG Therapeutics,
Inc. and Checkpoint Therapeutics, Inc. (“Checkpoint”), as previously extended on September 11, 2015, December 15, 2015,
and January 11, 2016.

 

1.Parties.
Effective March 17, 2015, Fortress Biotech, Inc. (“Fortress”) and Checkpoint entered into an agreement pursuant to
which Fortress assigned to Checkpoint all of its right and interests under the License Agreement.

 

2.Option Period.
Pursuant to Section 1.5 of the Option Agreement, the parties agree to further extend the Option Period for an additional 176 days,
with an expiration date of December 31, 2016.

 

3.Terms. This
Extension of Option Agreement shall be governed under all of the same terms as the Option Agreement.

 

4.Defined Terms.
Any capitalized term not defined in this Amendment shall be defined as defined in the Option Agreement.

 

5.Counterparts.
This Amendment may be executed by any party by PDF file signature, and on one or more counterparts, and by different parties on
separate counterparts, each of which shall be deemed to be an original as against any party whose signature appears thereon, all
of which together shall constitute but one and the same instrument.

 

 

TG Therapeutics, Inc.

2 Gansevoort Street, 9th Floor

New York, NY 10014

 

     

     

    

 

	 	Sincerely,
	 	TG Therapeutics, Inc.
	 	 
	 	/s/ Michael S. Weiss
	 	By: Michael S. Weiss
	 	Title: Executive Chairman, Interim CEO

 

Agreed and Accepted by:

Checkpoint Therapeutics, Inc.

 

	/s/ James Oliviero	 
	By: Mr. James Oliviero	 
	Title: CEO and President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00260-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00260-of-00352.parquet"}]]